JP2022081466A - Beverages containing collagen and iron - Google Patents
Beverages containing collagen and iron Download PDFInfo
- Publication number
- JP2022081466A JP2022081466A JP2021195865A JP2021195865A JP2022081466A JP 2022081466 A JP2022081466 A JP 2022081466A JP 2021195865 A JP2021195865 A JP 2021195865A JP 2021195865 A JP2021195865 A JP 2021195865A JP 2022081466 A JP2022081466 A JP 2022081466A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- iron
- liquid composition
- oral liquid
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000008186 Collagen Human genes 0.000 title claims abstract description 36
- 108010035532 Collagen Proteins 0.000 title claims abstract description 36
- 229920001436 collagen Polymers 0.000 title claims abstract description 35
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title claims description 78
- 229910052742 iron Inorganic materials 0.000 title claims description 39
- 235000013361 beverage Nutrition 0.000 title claims description 9
- 239000000284 extract Substances 0.000 claims abstract description 78
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 64
- 239000007788 liquid Substances 0.000 claims abstract description 48
- 239000000203 mixture Substances 0.000 claims abstract description 45
- 150000002506 iron compounds Chemical class 0.000 claims abstract description 27
- 244000019459 Cynara cardunculus Species 0.000 claims abstract description 18
- 235000019106 Cynara scolymus Nutrition 0.000 claims abstract description 18
- 239000000419 plant extract Substances 0.000 claims abstract description 15
- 239000009141 Houttuynia cordata plant extract Substances 0.000 claims abstract description 13
- 229940092258 rosemary extract Drugs 0.000 claims description 18
- 235000020748 rosemary extract Nutrition 0.000 claims description 18
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 claims description 18
- 235000016520 artichoke thistle Nutrition 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- PLKYGPRDCKGEJH-UHFFFAOYSA-N azane;2-hydroxypropane-1,2,3-tricarboxylic acid;iron Chemical compound N.[Fe].OC(=O)CC(O)(C(O)=O)CC(O)=O PLKYGPRDCKGEJH-UHFFFAOYSA-N 0.000 claims description 4
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 claims description 4
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 claims description 3
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 claims description 3
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims description 3
- 239000011773 ferrous fumarate Substances 0.000 claims description 3
- 235000002332 ferrous fumarate Nutrition 0.000 claims description 3
- 229960000225 ferrous fumarate Drugs 0.000 claims description 3
- 239000004222 ferrous gluconate Substances 0.000 claims description 3
- 235000013924 ferrous gluconate Nutrition 0.000 claims description 3
- 229960001645 ferrous gluconate Drugs 0.000 claims description 3
- 239000011790 ferrous sulphate Substances 0.000 claims description 3
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 3
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 3
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 3
- ATEAWHILRRXHPW-UHFFFAOYSA-J iron(2+);phosphonato phosphate Chemical compound [Fe+2].[Fe+2].[O-]P([O-])(=O)OP([O-])([O-])=O ATEAWHILRRXHPW-UHFFFAOYSA-J 0.000 claims description 3
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 3
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 claims description 3
- ZCFFYALKHPIRKJ-UHFFFAOYSA-N 3-[18-(2-carboxylatoethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-21,24-diium-2-yl]propanoate Chemical compound N1C(C=C2C(=C(C)C(=CC=3C(C)=C(CCC(O)=O)C(N=3)=C3)N2)C=C)=C(C)C(C=C)=C1C=C1C(C)=C(CCC(O)=O)C3=N1 ZCFFYALKHPIRKJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000011706 ferric diphosphate Substances 0.000 claims description 2
- 235000007144 ferric diphosphate Nutrition 0.000 claims description 2
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 claims description 2
- 229940036404 ferric pyrophosphate Drugs 0.000 claims description 2
- JHYAVWJELFKHLM-UHFFFAOYSA-H tetrasodium;2-hydroxypropane-1,2,3-tricarboxylate;iron(2+) Chemical compound [Na+].[Na+].[Na+].[Na+].[Fe+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O JHYAVWJELFKHLM-UHFFFAOYSA-H 0.000 claims description 2
- 229920002549 elastin Polymers 0.000 abstract description 30
- 102000016942 Elastin Human genes 0.000 abstract description 28
- 108010014258 Elastin Proteins 0.000 abstract description 28
- 244000178231 Rosmarinus officinalis Species 0.000 abstract description 3
- 229940074968 melissa officinalis extract Drugs 0.000 abstract 1
- 239000000843 powder Substances 0.000 description 30
- 239000003814 drug Substances 0.000 description 25
- 244000062730 Melissa officinalis Species 0.000 description 22
- 235000010654 Melissa officinalis Nutrition 0.000 description 20
- 229940079593 drug Drugs 0.000 description 18
- 235000019645 odor Nutrition 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000000047 product Substances 0.000 description 14
- 240000000691 Houttuynia cordata Species 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 241000196324 Embryophyta Species 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 235000013719 Houttuynia cordata Nutrition 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 235000013305 food Nutrition 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 241000251468 Actinopterygii Species 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000011259 mixed solution Substances 0.000 description 8
- 150000005846 sugar alcohols Polymers 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 6
- 239000004375 Dextrin Substances 0.000 description 5
- 229920001353 Dextrin Polymers 0.000 description 5
- -1 aliphatic alcohols Chemical class 0.000 description 5
- 235000019425 dextrin Nutrition 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 description 4
- 210000000709 aorta Anatomy 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- 235000013717 Houttuynia Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000269851 Sarda sarda Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229960000074 biopharmaceutical Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 210000003041 ligament Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 241000208838 Asteraceae Species 0.000 description 2
- 241001550206 Colla Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000207923 Lamiaceae Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 235000014171 carbonated beverage Nutrition 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229940109850 royal jelly Drugs 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000003198 Cynara Nutrition 0.000 description 1
- 241000208947 Cynara Species 0.000 description 1
- KHSCYOFDKADJDJ-NQLMQOPMSA-N Cynaropicrin Chemical compound OCC(=C)C(=O)O[C@H]1CC(=C)[C@@H]2C[C@H](O)C(=C)[C@@H]2[C@H]2OC(=O)C(=C)[C@H]12 KHSCYOFDKADJDJ-NQLMQOPMSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 241000272185 Falco Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000758742 Saururaceae Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- STQKFHDZSADKCG-UHFFFAOYSA-N cynaropicrin Natural products OC1CC2C(C3OC(=O)C(=C)C3C(CC2=C)OC(=O)C(=C)O)C1=C STQKFHDZSADKCG-UHFFFAOYSA-N 0.000 description 1
- 235000019543 dairy drink Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- XMXOIHIZTOVVFB-JIZZDEOASA-L disodium;(2s)-2-aminobutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CC([O-])=O XMXOIHIZTOVVFB-JIZZDEOASA-L 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 239000011640 ferrous citrate Substances 0.000 description 1
- 235000019850 ferrous citrate Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910000462 iron(III) oxide hydroxide Inorganic materials 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000019520 non-alcoholic beverage Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Non-Alcoholic Beverages (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Seasonings (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、鉄化合物を含有する経口液体組成物に関し、医薬品、医薬部外品及び食品等の分野において利用されうる。 The present invention relates to an oral liquid composition containing an iron compound and can be used in the fields of pharmaceuticals, quasi-drugs, foods and the like.
鉄は生体にとって必須の金属であるにも関わらず、特に女性において、摂取基準に対して不足しがちであることが報告されている。日本人の食事摂取基準(2020年版)において女性の鉄の推奨量は10.5mgであるが、平成30年国民健康・栄養調査では女性の鉄の摂取量は7.5mgであり、1日当たり3mg程度鉄が不足している(非特許文献1)。食生活上の効率的な摂取の方法として、鉄化合物を配合した飲料やサプリメント等が利用されているが、鉄化合物が他の配合成分と反応し、風味や品質を損なうという問題があった(特許文献1、2)。 Although iron is an essential metal for living organisms, it has been reported that it tends to be deficient in intake standards, especially in women. According to the Japanese Dietary Intake Standards (2020 Edition), the recommended amount of iron for women is 10.5 mg, but according to the 2018 National Health and Nutrition Survey, the intake of iron for women is 7.5 mg, which is 3 mg per day. There is a shortage of iron (Non-Patent Document 1). Beverages and supplements containing iron compounds are used as an efficient method of ingestion in terms of eating habits, but there is a problem that iron compounds react with other ingredients and impair flavor and quality ( Patent Documents 1 and 2).
また、近年、コラーゲンペプチドやエラスチンペプチドを配合した飲料やサプリメントの人気が高まっている。コラーゲンは、真皮、靭帯、腱、骨、軟骨などを構成する主要なタンパク質である。(非特許文献2)。コラーゲンペプチドは、動物や魚から得られたコラーゲンを加水分解する等の方法で得られる。エラスチンは、項靭帯、大動脈、皮膚、肺など弾性を必要とする様々な組織に広く分布している線維の主要タンパク質である(非特許文献3)。 In recent years, beverages and supplements containing collagen peptide and elastin peptide have become more popular. Collagen is a major protein that constitutes the dermis, ligaments, tendons, bones, cartilage, etc. (Non-Patent Document 2). Collagen peptide is obtained by a method such as hydrolyzing collagen obtained from animals or fish. Elastin is a major protein of fibers widely distributed in various tissues requiring elasticity such as nuchal ligament, aorta, skin, and lung (Non-Patent Document 3).
エラスチンペプチドは、動物の大動脈や魚の動脈球等を原料として加水分解する等の方法で得られる。このように、コラーゲンペプチドやエラスチンペプチドは、豚や魚由来のタンパク質を原料として得られるため、特有の不快臭を有する。 The elastin peptide can be obtained by a method such as hydrolysis using an aorta of an animal, an arterial bulb of a fish, or the like as a raw material. As described above, collagen peptide and elastin peptide have a peculiar unpleasant odor because they are obtained from proteins derived from pigs and fish.
今までに、コラーゲン加水分解物を配合した風味の良好な飲料として、ハトムギエキス、ベニバナエキス、アンズエキスおよびニンジンエキスよりなる群から選ばれる2種以上のエキス、ローヤルゼリー、ビタミンB2類およびビタミンB6類から選ばれる1種または2種以上のビタミン、食物繊維、糖類、ステビア、梅果汁、L-アスパラギン酸ナトリウム、酸味剤およびフルーツ系フレーバーを配合した飲料が報告されている(特許文献3)。 So far, two or more kinds of extracts selected from the group consisting of honeybee extract, benibana extract, apricot extract and carrot extract, royal jelly, vitamin B2 and vitamin B6 as a good-tasting beverage containing collagen hydrolyzate. Beverages containing one or more vitamins, dietary fiber, sugars, stevia, plum juice, sodium L-aspartate, acidulants and fruit flavors selected from the above have been reported (Patent Document 3).
本発明者らは、コラーゲンペプチド又はエラスチンペプチドを配合した経口液体組成物に、鉄化合物を配合したところ、特有の不快臭が増強することを発見した。よって本発明の目的は、この特有の不快臭を抑制し、日常的に摂取可能な嗜好性の高い経口液体組成物を提供することである。 The present inventors have found that when an iron compound is added to an oral liquid composition containing a collagen peptide or an elastin peptide, the peculiar unpleasant odor is enhanced. Therefore, an object of the present invention is to suppress this peculiar unpleasant odor and to provide a highly palatable oral liquid composition that can be ingested on a daily basis.
この問題を解決すべく鋭意検討を重ねた結果、特定の植物エキスを配合すると、鉄化合物とコラーゲンペプチド又はエラスチンペプチドを組み合わせた際の特有の不快臭を抑制できることを見出し、本発明を完成するに至った。 As a result of diligent studies to solve this problem, it was found that the addition of a specific plant extract can suppress the peculiar unpleasant odor when the iron compound is combined with collagen peptide or elastin peptide, and the present invention is completed. I arrived.
かかる知見により得られた本発明の態様は次のとおりである。
(1)(A)鉄化合物、
(B)コラーゲンペプチド及びエラスチンペプチドからなる群から選ばれる少なくとも1種のペプチド、
(C)レモンバームエキス、ドクダミエキス、アーティチョークエキス、及びローズマリーエキスからなる群から選ばれる少なくとも1種の植物エキス、を含有することを特徴とする経口液体組成物、
(2)(A)鉄化合物の含有量が、鉄換算で0.0002~0.2w/v%である(1)に記載の経口液体組成物、
(3)(B)コラーゲンペプチドの含有量が、0.02~20w/v%である(1)又は(2)に記載の経口液体組成物、
(4)(B)エラスチンペプチドの含有量が、0.0002~2w/v%である(1)~(3)のいずれかに記載の経口液体組成物、
(5)(C)のレモンバームエキス、ドクダミエキス、アーティチョークエキス、及びローズマリーエキスからなる群から選ばれる少なくとも1種の植物エキスの含有量が0.0002~2w/v%である(1)~(4)のいずれかに記載の経口液体組成物、
(6)鉄化合物が、フマル酸第一鉄、塩化第二鉄、クエン酸鉄、クエン酸鉄アンモニウム、クエン酸第一鉄ナトリウム、グルコン酸第一鉄、乳酸鉄、ピロリン酸第一鉄、ピロリン酸第二鉄、硫酸第一鉄およびヘム鉄からなる群から選ばれる少なくとも1種である(1)~(5)のいずれかに記載の経口液体組成物、
(7)pHが2.5~4.5である(1)~(6)のいずれかに記載の経口液体組成物、
(8)経口液体組成物が、液体飲料である(1)~(7)のいずれかに記載の経口液体組成物、
(9)鉄化合物に、コラーゲンペプチド又はエラスチンペプチドを配合することで生じる不快臭を、レモンバームエキス、ドクダミエキス、アーティチョークエキス、及びローズマリーエキスからなる群から選ばれる少なくとも1種の植物エキスを配合することにより抑制する方法、
である。
The aspects of the present invention obtained from such findings are as follows.
(1) (A) Iron compound,
(B) At least one peptide selected from the group consisting of collagen peptide and elastin peptide,
(C) An oral liquid composition comprising at least one plant extract selected from the group consisting of lemon balm extract, Houttuynia cordata extract, artichoke extract, and rosemary extract.
(2) The oral liquid composition according to (1), wherein the content of the iron compound (A) is 0.0002 to 0.2 w / v% in terms of iron.
(3) The oral liquid composition according to (1) or (2), wherein the content of (B) collagen peptide is 0.02 to 20 w / v%.
(4) The oral liquid composition according to any one of (1) to (3), wherein the content of (B) elastin peptide is 0.0002 to 2 w / v%.
(5) The content of at least one plant extract selected from the group consisting of lemon balm extract, Houttuynia cordata extract, artichoke extract, and rosemary extract of (C) is 0.0002 to 2 w / v% (1) to. The oral liquid composition according to any one of (4),
(6) The iron compound is ferrous fumarate, ferric chloride, iron citrate, ammonium iron citrate, sodium ferrous citrate, ferrous gluconate, iron lactate, ferrous pyrophosphate, pyrrolin. The oral liquid composition according to any one of (1) to (5), which is at least one selected from the group consisting of ferric acid acid, ferrous sulfate and iron hem.
(7) The oral liquid composition according to any one of (1) to (6), which has a pH of 2.5 to 4.5.
(8) The oral liquid composition according to any one of (1) to (7), wherein the oral liquid composition is a liquid beverage.
(9) At least one plant extract selected from the group consisting of lemon balm extract, dokudami extract, artichoke extract, and rosemary extract is blended with the unpleasant odor generated by blending collagen peptide or elastin peptide with the iron compound. How to suppress by
Is.
本発明により、鉄化合物とコラーゲンペプチド又はエラスチンペプチドを配合した際の特有の不快臭が抑制された経口液体組成物を提供することが可能となった。 INDUSTRIAL APPLICABILITY According to the present invention, it has become possible to provide an oral liquid composition in which a peculiar unpleasant odor when an iron compound and a collagen peptide or an elastin peptide are blended is suppressed.
本発明において「鉄化合物」とは、二価の鉄化合物及び三価の鉄化合物のいずれでもよく、例えばフマル酸第一鉄、塩化第二鉄、クエン酸鉄、クエン酸鉄アンモニウム、クエン酸第一鉄ナトリウム、グルコン酸第一鉄、乳酸鉄、ピロリン酸第一鉄、ピロリン酸第二鉄、硫酸第一鉄、ヘム鉄を挙げることができる。鉄化合物の含有量は、鉄の含有量が高くなるにつれ、コラーゲンペプチド又はエラスチンペプチドと配合した際の不快臭の割合が増加するため、鉄の含有量が高くなるほど実施する意義が高い。本発明の経口液体組成物中、鉄換算で下限値は0.0002w/v%が好ましく、0.001w/v%がより好ましく、0.002w/v%がさらに好ましく、0.006w/v%がさらに好ましく、0.01w/v%が最も好ましい。また、鉄化合物としては下限値は0.001w/v%が好ましく、0.005w/v%がより好ましく、0.01w/v%がさらに好ましく0.02w/v%がさらに好ましく、0.03w/v%がさらに好ましく、0.05w/v%が最も好ましい。なお、本発明のコラーゲンペプチドとレモンバームエキスを配合する場合は、本発明の経口液体組成物中、鉄換算で下限値は好ましくは0.006w/v%、より好ましくは0.01w/v%であり、鉄化合物としては下限値は好ましくは0.03w/v%、より好ましくは0.05w/v%である。また、上限値としては、本発明の経口液体組成物中、鉄換算としては上限値は0.2w/v%が好ましく、0.04w/v%がより好ましい。また、鉄化合物の上限値は3.3w/v%が好ましく、1.2w/v%がより好ましい。 In the present invention, the "iron compound" may be either a divalent iron compound or a trivalent iron compound, for example, ferrous fumarate, ferric chloride, iron citrate, ammonium iron citrate, or ferrous citrate. Examples thereof include sodium monoferric acid, ferrous gluconate, iron lactate, ferrous pyrophosphate, ferric pyrophosphate, ferrous sulfate, and hem iron. As the iron content increases, the proportion of unpleasant odor when blended with collagen peptide or elastin peptide increases, so the higher the iron content, the more significant the implementation. In the oral liquid composition of the present invention, the lower limit in terms of iron is preferably 0.0002 w / v%, more preferably 0.001 w / v%, further preferably 0.002 w / v%, and 0.006 w / v%. Is more preferable, and 0.01 w / v% is most preferable. The lower limit of the iron compound is preferably 0.001 w / v%, more preferably 0.005 w / v%, further preferably 0.01 w / v%, further preferably 0.02 w / v%, and 0.03 w. / V% is more preferable, and 0.05 w / v% is most preferable. When the collagen peptide of the present invention and the lemon balm extract are blended, the lower limit in terms of iron is preferably 0.006 w / v%, more preferably 0.01 w / v% in the oral liquid composition of the present invention. The lower limit of the iron compound is preferably 0.03 w / v%, more preferably 0.05 w / v%. Further, as the upper limit value, in the oral liquid composition of the present invention, the upper limit value is preferably 0.2 w / v%, more preferably 0.04 w / v% in terms of iron. The upper limit of the iron compound is preferably 3.3 w / v%, more preferably 1.2 w / v%.
本発明において「コラーゲンペプチド」とは、その起源は特に限定されず、合成であってもよく、牛や豚等の家畜や魚を加工する際に副生する皮、骨、靭帯、腱、軟骨等から抽出して製造されるコラーゲンペプチドであってもよいが、豚および魚由来のコラーゲンペプチドが好ましい。コラーゲンタンパク質を酵素や化学的処理等により分解して得られるコラーゲンペプチドが好ましい。コラーゲンペプチドの平均分子量としては、特に限定されないが、500~50000であることが好ましく、1000~25000であることがより好ましい。コラーゲンペプチドの含有量は、本発明の経口液体組成物中、0.02~20w/v%であることが好ましく、0.1~15w/v%がより好ましい。 In the present invention, the origin of the "collagen peptide" is not particularly limited and may be synthetic, and the skin, bone, ligament, tendon, and cartilage produced as a by-product when processing livestock such as cows and pigs and fish It may be a collagen peptide produced by extracting from the above, but a collagen peptide derived from pig and fish is preferable. A collagen peptide obtained by decomposing collagen protein by enzyme, chemical treatment or the like is preferable. The average molecular weight of the collagen peptide is not particularly limited, but is preferably 500 to 50,000, and more preferably 1,000 to 25,000. The content of the collagen peptide is preferably 0.02 to 20 w / v%, more preferably 0.1 to 15 w / v% in the oral liquid composition of the present invention.
本発明のコラーゲンペプチドは、市販品を用いてもよく、例えば、(株)ニッピ製の「ニッピペプタイドPS-1」、「ニッピペプタイドPRA-P」、「ニッピペプタイドFCP-EX」、ゼライス(株)製の「HACP-CF」、「HACP-TF」、新田ゼラチン(株)製の「コラペプPU」、「コラペプJB」、「HDL-50SP」、「SCP-3100」、ルスロ(株)製の「peptan P2000HD」等が挙げられる。
本発明の「コラーゲンペプチド」の含有量は、鉄換算で鉄1質量部に対して1~75000質量部が好ましく、5~7500質量部がより好ましく、20~2500質量部がさらに好ましい。
As the collagen peptide of the present invention, a commercially available product may be used, for example, "Nippi Peptide PS-1", "Nippi Peptide PRA-P", "Nippi Peptide FCP-EX", and gelatin (Nippi Peptide FCP-EX) manufactured by Nippi Co., Ltd. ) "HACP-CF", "HACP-TF", Nitta Gelatin Co., Ltd. "Colla Peptide PU", "Colla Peptide JB", "HDL-50SP", "SCP-3100", Lusulo Co., Ltd. "Peptan P2000HD" and the like can be mentioned.
The content of the "collagen peptide" of the present invention is preferably 1 to 75,000 parts by mass, more preferably 5 to 7500 parts by mass, still more preferably 20 to 2500 parts by mass with respect to 1 part by mass of iron in terms of iron.
本発明において「エラスチンペプチド」とは、その起源は特に限定されず、合成であってもよく、動物の大動脈や魚の動脈球等を、酵素等を用いて加水分解して製造されるものであってもよいが、豚大動脈およびカツオ動脈球由来のエラスチンペプチドが好ましい。本発明のエラスチンペプチドは、市販品を用いても良く、例えば、日本ハム(株)製の「P-エラスチン」、林兼産業(株)の「カツオエラスチン」、日本水産(株)製の「美弾エラスチン」等が挙げられる。エラスチンペプチドの分子量は特に限定されないが、100~20000であることが好ましく、150~10000であることがより好ましい。 In the present invention, the "elastin peptide" is not particularly limited in its origin and may be synthesized, and is produced by hydrolyzing an aorta of an animal, an arterial sphere of a fish, or the like with an enzyme or the like. However, elastin peptides derived from porcine aorta and bonito arterial bulb are preferred. As the elastin peptide of the present invention, a commercially available product may be used, for example, "P-elastin" manufactured by Nippon Ham Co., Ltd., "bonito elastin" manufactured by Hayashikane Sangyo Co., Ltd., and "Beauty" manufactured by Nippon Suisan Kaisha Co., Ltd. Bullet elastin "and the like. The molecular weight of the elastin peptide is not particularly limited, but is preferably 100 to 20000, and more preferably 150 to 10000.
エラスチンペプチドの含有量は、本発明の経口液体組成物中、0.0002~2w/v%であることが好ましく、0.002~1w/v%がより好ましい。 The content of the elastin peptide is preferably 0.0002 to 2 w / v%, more preferably 0.002 to 1 w / v% in the oral liquid composition of the present invention.
本発明の「エラスチンペプチド」の含有量は、鉄換算で鉄1質量部に対して0.1~5000質量部が好ましく、0.5~500質量部がより好ましく、0.5~100質量部がさらに好ましい。 The content of the "elastin peptide" of the present invention is preferably 0.1 to 5000 parts by mass, more preferably 0.5 to 500 parts by mass, and 0.5 to 100 parts by mass with respect to 1 part by mass of iron in terms of iron. Is even more preferable.
本発明のレモンバームとは、シソ科コウスイハッカ属のレモンバーム(別名:メリッサ、学名:Melissa officinalis)の葉に由来する生薬又は植物であり、生薬末又は植物末、生薬エキス又は植物エキスの形で使用される。本発明に用いる生薬末又は植物末としては、例えば乾燥刻み加工品を更に細かく粉砕した粉末状の乾燥品としてもよい。 The lemon balm of the present invention is a crude drug or plant derived from the leaves of a lemon balm of the genus Melissa of the Labiatae family (also known as Melissa, scientific name: Melissa officinalis), and is used in the form of crude drug powder or plant powder, crude drug extract or plant extract. Will be done. The crude drug powder or plant powder used in the present invention may be, for example, a powdered dried product obtained by further finely crushing a dried chopped product.
本発明に用いる「レモンバームエキス」は、水、低級脂肪族アルコール(メタノール、エタノール、イソプロピルアルコールなど)、多価アルコール(1,3-ブチレングリコール、プロピレングリコール、ジプロピレングリコール、グリセリンなど)、低級脂肪族ケトン(アセトンなど)などの溶媒や前記溶媒の混液により抽出したものを使用することができるが、このうち水、低級脂肪族アルコール、多価アルコール又はこれらの混液で抽出することが最も好ましい。
また、エキスの形態は特に制限されるものではなく、加熱処理、凍結乾燥あるいは減圧乾燥、デキストリン等の賦形剤を加えた粉末化などの処理により、乾燥エキス末、エキス末、軟エキス、流エキスなどにすることができる。レモンバームエキスの市販品としては、丸善製薬(株)の「レモンバームエキスA」、「レモンバームエキスパウダーMF」、一丸ファルコス(株)の「ファルコレックス メリッサB」等が挙げられる。
The "lemon balm extract" used in the present invention includes water, lower aliphatic alcohols (methanol, ethanol, isopropyl alcohol, etc.), polyhydric alcohols (1,3-butylene glycol, propylene glycol, dipropylene glycol, glycerin, etc.), lower fats. A solvent such as a group ketone (such as acetone) or one extracted by a mixed solution of the above-mentioned solvent can be used, but it is most preferable to extract with water, a lower aliphatic alcohol, a polyhydric alcohol or a mixed solution thereof.
The form of the extract is not particularly limited, and dried extract powder, extract powder, soft extract, or stream can be obtained by heat treatment, freeze-drying or vacuum-drying, or powdering with an excipient such as dextrin. It can be an extract or the like. Examples of commercially available products of lemon balm extract include "Lemon balm extract A" and "Lemon balm extract powder MF" of Maruzen Pharmaceuticals Co., Ltd., and "Falcolex Melissa B" of Ichimaru Falcos Co., Ltd.
レモンバームエキスの含有量は、賦形剤や抽出溶媒等を除いた正味のレモンバームエキスとして、本発明の効果の点から、本発明の経口液体組成物中0.0002w/v%以上が好ましく、0.001w/v%以上がより好ましい。上限値は、風味の観点から、2w/v%が好ましく、0.5w/v%がより好ましく、0.25w/v%が最も好ましい。鉄とレモンバームを配合するときは、レモンバームエキスの含有量は、本発明の効果の点から、鉄換算で、鉄1質量部に対して0.001質量部以上が好ましく、0.005質量部以上がより好ましい。上限値は鉄換算で鉄1質量部に対して10000質量部が好ましく、1250質量部がより好ましく、125質量部がさらに好ましい。 The content of the lemon balm extract is preferably 0.0002 w / v% or more in the oral liquid composition of the present invention, preferably 0, as a net lemon balm extract excluding excipients and extraction solvents from the viewpoint of the effect of the present invention. More preferably, it is 001 w / v% or more. The upper limit is preferably 2 w / v%, more preferably 0.5 w / v%, and most preferably 0.25 w / v% from the viewpoint of flavor. When iron and lemon balm are blended, the content of lemon balm extract is preferably 0.001 part by mass or more, preferably 0.005 part by mass or more, based on 1 part by mass of iron in terms of iron, from the viewpoint of the effect of the present invention. Is more preferable. The upper limit is preferably 10000 parts by mass, more preferably 1250 parts by mass, and even more preferably 125 parts by mass with respect to 1 part by mass of iron in terms of iron.
本発明のドクダミはコショウ目ドクダミ科ドクダミ属ドクダミHouttuynia cordata Thunberg(Saururaceae)の開花期の地上部に由来する生薬又は植物であり、生薬末又は植物末、生薬エキス又は植物エキスの形で使用される。本発明に用いる生薬末又は植物末としては、例えば乾燥刻み加工品を更に細かく粉砕した粉末状の乾燥品としてもよい。
本発明に用いる「ドクダミエキス」は、水、低級脂肪族アルコール(メタノール、エタノール、イソプロピルアルコールなど)、多価アルコール(1,3-ブチレングリコール、プロピレングリコール、ジプロピレングリコール、グリセリンなど)、低級脂肪族ケトン(アセトンなど)などの溶媒や前記溶媒の混液により抽出したものを使用することができるが、このうち水、低級脂肪族アルコール、多価アルコール又はこれらの混液で抽出することが最も好ましい。
The Houttuynia of the present invention is a raw medicine or plant derived from the above-ground part of the flowering period of Houttuynia cordata Thunberg (Saururaceae) of the family Houttuynia, Houttuynia, and is used in the form of raw medicine powder or plant powder, raw medicine extract or plant extract. .. The crude drug powder or plant powder used in the present invention may be, for example, a powdered dried product obtained by further finely crushing a dried chopped product.
The "dokudami extract" used in the present invention includes water, lower aliphatic alcohols (methanol, ethanol, isopropyl alcohol, etc.), polyhydric alcohols (1,3-butylene glycol, propylene glycol, dipropylene glycol, glycerin, etc.), lower fats. A solvent such as a group ketone (such as acetone) or one extracted by a mixed solution of the above-mentioned solvent can be used, but it is most preferable to extract with water, a lower aliphatic alcohol, a polyhydric alcohol or a mixed solution thereof.
また、エキスの形態は特に制限されるものではなく、加熱処理、凍結乾燥あるいは減圧乾燥、デキストリン等の賦形剤を加えた粉末化などの処理により、乾燥エキス末、エキス末、軟エキス、流エキスなどにすることができる。ドクダミエキスの市販品としては、丸善製薬(株)の「ジュウヤク抽出液」、「ジュウヤク抽出液BG」、「ドクダミエキスパウダーMF」や、一丸ファルコス(株)の「ファルコレックス ドクダミ B」、「ファルコレックス ドクダミ E」、「ファルコレックス ドクダミ W」、「ドクダミDXP100」等が挙げられる。 The form of the extract is not particularly limited, and dried extract powder, extract powder, soft extract, or stream can be obtained by heat treatment, freeze-drying or vacuum-drying, or powdering with an excipient such as dextrin. It can be an extract or the like. Commercial products of Houttuynia cordata extract include Maruzen Pharmaceuticals Co., Ltd.'s "Juyaku extract", "Juyaku extract BG", "Houttuynia cordata extract powder MF", and Ichimaru Falcos Co., Ltd. "Falcolex Dokudami B", "Falco". Examples include "Rex Houttuynia cordata E", "Falco Rex Houttuynia cordata W", and "Houttuynia cordata DXP100".
ドクダミエキスの含有量は、賦形剤や抽出溶媒等を除いた正味のドクダミエキスとして、本発明の効果の点から、本発明の経口液体組成物中0.0002w/v%以上が好ましく、0.002w/v%以上がより好ましい。上限値は、風味の観点から2w/v%が好ましく、0.2w/v%がより好ましい。ドクダミエキスの含有量は、本発明の効果の点から、鉄換算で、鉄1質量部に対して0.001質量部以上が好ましく、0.01質量部以上がより好ましく、0.05質量部以上がさらに好ましい。上限値は鉄換算で鉄1質量部に対して10000質量部が好ましく、1000質量部がより好ましく、100質量部がさらに好ましい。 The content of Houttuynia cordata extract is preferably 0.0002 w / v% or more in the oral liquid composition of the present invention, preferably 0, as a net Houttuynia cordata extract excluding excipients and extraction solvents from the viewpoint of the effect of the present invention. More preferably, it is .002 w / v% or more. The upper limit is preferably 2 w / v%, more preferably 0.2 w / v%, from the viewpoint of flavor. From the viewpoint of the effect of the present invention, the content of Houttuynia cordata extract is preferably 0.001 part by mass or more, more preferably 0.01 part by mass or more, and 0.05 part by mass with respect to 1 part by mass of iron in terms of iron. The above is more preferable. The upper limit is preferably 10,000 parts by mass, more preferably 1000 parts by mass, and even more preferably 100 parts by mass with respect to 1 part by mass of iron in terms of iron.
本発明のアーティチョークは、キク目キク科チョウセンアザミ属アーティチョークCynara scolymus Linne (Compositae)の葉に由来する生薬又は植物であり、生薬末又は植物末、生薬エキス又は植物エキスの形で使用される。本発明に用いる生薬末又は植物末としては、例えば乾燥刻み加工品を更に細かく粉砕した粉末状の乾燥品としてもよい。
本発明に用いる「アーティチョークエキス」は、水、低級脂肪族アルコール(メタノール、エタノール、イソプロピルアルコールなど)、多価アルコール(1,3-ブチレングリコール、プロピレングリコール、ジプロピレングリコール、グリセリンなど)、低級脂肪族ケトン(アセトンなど)などの溶媒や前記溶媒の混液により抽出したものを使用することができるが、このうち水、低級脂肪族アルコール、多価アルコール又はこれらの混液で抽出することが最も好ましい。
また、エキスの形態は特に制限されるものではなく、加熱処理、凍結乾燥あるいは減圧乾燥、デキストリン等の賦形剤を加えた粉末化などの処理により、乾燥エキス末、エキス末、軟エキス、流エキスなどにすることができる。アーティチョークエキスの市販品としては、一丸ファルコス(株)の「バイオベネフィティ(登録商標)」、「バイオベネフィティ G」、「バイオベネフィティ HS」、「シナロピクリン F」、「バイオベネフィティ F」等が挙げられる。
The artichoke of the present invention is a biopharmaceutical or plant derived from the leaves of Cynara scolymus Linne (Compositae), which belongs to the genus Cynara of the Asteraceae family, and is used in the form of biopharmaceutical powder or plant powder, biopharmaceutical extract or plant extract. The crude drug powder or plant powder used in the present invention may be, for example, a powdered dried product obtained by further finely crushing a dried chopped product.
The "artichoke extract" used in the present invention includes water, lower aliphatic alcohols (methanol, ethanol, isopropyl alcohol, etc.), polyhydric alcohols (1,3-butylene glycol, propylene glycol, dipropylene glycol, glycerin, etc.), lower fats. A solvent such as a group ketone (such as acetone) or one extracted by a mixed solution of the above-mentioned solvent can be used, but it is most preferable to extract with water, a lower aliphatic alcohol, a polyhydric alcohol or a mixed solution thereof.
The form of the extract is not particularly limited, and dried extract powder, extract powder, soft extract, or stream can be obtained by heat treatment, freeze-drying or vacuum-drying, or powdering with an excipient such as dextrin. It can be an extract or the like. Commercially available products of artichoke extract include "Biobenefity (registered trademark)", "Biobenefity G", "Biobenefity HS", "Cynaropicrin F", "Biobenefity F", etc. of Ichimaru Falcos Co., Ltd. Can be mentioned.
アーティチョークエキスの含有量は、賦形剤や抽出溶媒等を除いた正味のアーティチョークエキスとして、本発明の効果の点から、本発明の経口液体組成物中0.0002w/v%以上が好ましく、0.0006w/v%以上がより好ましい。上限値は、風味の観点から2w/v%が好ましく、0.06w/v%がより好ましい。アーティチョークエキスの含有量は、本発明の効果の点から、鉄換算で鉄1質量部に対して0.001質量部以上部が好ましく、0.003質量部以上がより好ましく、0.015質量部以上がさらに好ましい。上限値は、鉄換算で鉄1質量部に対して10000質量部が好ましく、300質量部がより好ましく、30質量部がさらに好ましい。 The content of the artichoke extract is preferably 0.0002 w / v% or more in the oral liquid composition of the present invention, preferably 0, as a net artichoke extract excluding excipients and extraction solvents from the viewpoint of the effect of the present invention. 0006 w / v% or more is more preferable. The upper limit is preferably 2 w / v%, more preferably 0.06 w / v%, from the viewpoint of flavor. From the viewpoint of the effect of the present invention, the content of the artichoke extract is preferably 0.001 part by mass or more, more preferably 0.003 part by mass or more, and 0.015 part by mass with respect to 1 part by mass of iron in terms of iron. The above is more preferable. The upper limit is preferably 10,000 parts by mass, more preferably 300 parts by mass, and even more preferably 30 parts by mass with respect to 1 part by mass of iron in terms of iron.
本発明のローズマリーとは、シソ科植物ローズマリー(学名:Rosmarinus Officinalis)の葉に由来する生薬または植物であり、生薬末又は植物末、生薬エキス又は植物エキスの形で使用される。本発明に用いる生薬末又は植物末としては、例えば乾燥刻み加工品を更に細かく粉砕した粉末状の乾燥品としてもよい。発明に用いる「ローズマリーエキス」は、水、低級脂肪族アルコール(メタノール、エタノール、イソプロピルアルコールなど)、多価アルコール(1,3-ブチレングリコール、プロピレングリコール、ジプロピレングリコール、グリセリンなど)、低級脂肪族ケトン(アセトンなど)などの溶媒や前記溶媒の混液により抽出したものを使用することができるが、このうち水、低級脂肪族アルコール、多価アルコール又はこれらの混液で抽出することが最も好ましい。
また、エキスの形態は特に制限されるものではなく、加熱処理、凍結乾燥あるいは減圧乾燥、デキストリン等の賦形剤を加えた粉末化などの処理により、乾燥エキス末、エキス末、軟エキス、流エキスなどにすることができる。ローズマリーエキスの市販品としては、本発明に用いるまた抽出物である。エキス末として、市販品を用いても良く、「ローズマリーエキス(バイオアクティブズジャパン)」、「ローズマリーエキスMF(丸善製薬)」等が挙げられる。
The rosemary of the present invention is a crude drug or plant derived from the leaves of the Labiatae plant rosemary (scientific name: Rosamarinus Officinalis), and is used in the form of crude drug powder or plant powder, raw drug extract or plant extract. The crude drug powder or plant powder used in the present invention may be, for example, a powdered dried product obtained by further finely crushing a dried chopped product. The "rosemary extract" used in the invention includes water, lower aliphatic alcohols (methanol, ethanol, isopropyl alcohol, etc.), polyhydric alcohols (1,3-butylene glycol, propylene glycol, dipropylene glycol, glycerin, etc.), lower fats. A solvent such as a group ketone (such as acetone) or one extracted by a mixed solution of the above-mentioned solvent can be used, but it is most preferable to extract with water, a lower aliphatic alcohol, a polyhydric alcohol or a mixed solution thereof.
The form of the extract is not particularly limited, and dried extract powder, extract powder, soft extract, or stream can be obtained by heat treatment, freeze-drying or vacuum-drying, or powdering with an excipient such as dextrin. It can be an extract or the like. As a commercial product of rosemary extract, it is also an extract used in the present invention. As the extract powder, a commercially available product may be used, and examples thereof include "rosemary extract (Bioactives Japan)" and "rosemary extract MF (Maruzen Pharmaceuticals)".
ローズマリーエキスの含有量は、賦形剤や抽出溶媒等を除いた正味のローズマリーエキスとして、本発明の効果の点から、本発明の経口液体組成物中0.0002w/v%以上が好ましく、0.0008w/v%以上がより好ましい。上限値は、風味の観点から、2w/v%が好ましく、0.1w/v%がより好ましい。ローズマリーエキスの含有量は、本発明の効果の点から、鉄換算で、鉄1質量部に対して0.001質量部以上が好ましく、0.004質量部以上がより好ましく、0.02質量部以上がさらに好ましい。上限値は鉄換算で鉄1質量部に対して10000質量部が好ましく、500質量部がより好ましく、50質量部がさらに好ましい。 The content of the rosemary extract is preferably 0.0002 w / v% or more in the oral liquid composition of the present invention from the viewpoint of the effect of the present invention as a net rosemary extract excluding excipients and extraction solvents. , 0.0008 w / v% or more is more preferable. The upper limit is preferably 2 w / v%, more preferably 0.1 w / v%, from the viewpoint of flavor. From the viewpoint of the effect of the present invention, the content of the rosemary extract is preferably 0.001 part by mass or more, more preferably 0.004 part by mass or more, and 0.02 mass by mass with respect to 1 part by mass of iron in terms of iron. More than a portion is more preferable. The upper limit is preferably 10,000 parts by mass, more preferably 500 parts by mass, and even more preferably 50 parts by mass with respect to 1 part by mass of iron in terms of iron.
本発明は、鉄化合物とコラーゲンペプチド又はエラスチンペプチドを配合した際の不快臭を、特定の植物エキス、すなわちレモンバームエキス、ドクダミエキス、アーティチョークエキス、又はローズマリーエキスを配合することで顕著に抑制できる。 INDUSTRIAL APPLICABILITY The present invention can remarkably suppress the unpleasant odor when an iron compound and a collagen peptide or an elastin peptide are blended by blending a specific plant extract, that is, a lemon balm extract, a dokudami extract, an artichoke extract, or a rosemary extract.
本発明における経口液体組成物とは、経口摂取できる液体であれば特に制限はなく、医薬品、医薬部外品、又は食品(一般の食品だけでなく、栄養機能性食品や特定保健用食品、機能性表示食品も含む)を挙げることができる。 The oral liquid composition in the present invention is not particularly limited as long as it is a liquid that can be orally ingested, and is a drug, a quasi-drug, or a food (not only general foods, but also nutritionally functional foods, foods for specified health uses, and functions. (Including quasi-drugs).
医薬品及び医薬部外品としては、例えば内服液剤、ドリンク剤等を挙げることができる。食品としては、清涼飲料水、炭酸飲料、スポーツ・機能性飲料、ノンアルコール飲料、乳飲料、茶飲料、コーヒー飲料、果実・野菜系飲料、ゼリー飲料等が挙げられる。より好ましくは、医薬品及び医薬部外品であれば内服液剤、ドリンク剤、食品であれば、栄養機能性食品、特定保健用食品等の各種飲料、炭酸飲料、ゼリー飲料である。 Examples of pharmaceuticals and quasi-drugs include internal liquids and drinks. Examples of foods include soft drinks, carbonated drinks, sports / functional drinks, non-alcoholic drinks, dairy drinks, tea drinks, coffee drinks, fruit / vegetable drinks, jelly drinks and the like. More preferably, it is an internal liquid or drink for pharmaceuticals and quasi-drugs, and various beverages such as nutritionally functional foods and foods for specified health use, carbonated beverages and jelly beverages for foods.
本発明の経口液体組成物のpHは、特に限定されないが、口当たりの良さという点から2.5~4.5が好ましく、3.0~4.0がより好ましい。pHを上記範囲に保つために、必要に応じて有機酸等のpH調整剤を配合することができる。 The pH of the oral liquid composition of the present invention is not particularly limited, but is preferably 2.5 to 4.5, more preferably 3.0 to 4.0, from the viewpoint of good mouthfeel. In order to keep the pH in the above range, a pH adjuster such as an organic acid can be added as needed.
本発明の経口液体組成物は、常法により製造することができ、その方法は特に限定され
るものではない。通常、各成分を量りとり、適量の精製水で溶解、撹拌した後、pHを調
整し、さらに精製水を加えて容量調整し、必要に応じてろ過、殺菌処理を施すことにより
得られる。
The oral liquid composition of the present invention can be produced by a conventional method, and the method is not particularly limited. Usually, it is obtained by weighing each component, dissolving and stirring with an appropriate amount of purified water, adjusting the pH, further adding purified water to adjust the volume, and performing filtration and sterilization treatment as necessary.
また、本発明の経口液体組成物には、その他の成分として、ビタミン類、ミネラル類、アミノ酸及びその塩類、生薬、生薬抽出物、カフェイン、ローヤルゼリー、デキストリン等を本発明の効果を損なわない範囲で適宜に配合することができる。さらに必要に応じて、抗酸化剤、着色剤、香料、矯味剤、保存剤、甘味料、酸味剤等の添加物を本発明の効果を損なわない範囲で適宜に配合することができる。 Further, in the oral liquid composition of the present invention, as other components, vitamins, minerals, amino acids and salts thereof, crude drugs, crude drug extracts, caffeine, royal jelly, dextrin and the like are included as long as the effects of the present invention are not impaired. Can be appropriately blended with. Further, if necessary, additives such as antioxidants, colorants, flavors, flavoring agents, preservatives, sweeteners, and acidulants can be appropriately blended as long as the effects of the present invention are not impaired.
以下に、実施例、比較例を挙げ、本発明を更に詳細に説明する。 Hereinafter, the present invention will be described in more detail with reference to Examples and Comparative Examples.
(比較例1~18、実施例1-1~18)
下記表1~10に記載の処方および次の方法に従い経口液体組成物を調製した。まず、全量の60%程度の精製水に、コラーゲンペプチド(豚由来:新田ゼラチン株式会社製コラペプJB、株式会社ニッピ製ニッピぺプタイドPRA-P、魚由来:株式会社ニッピ製ニッピペプタイドFCP-EX)、又はエラスチンペプチド(魚由来:林兼産業株式会社製カツオエラスチン、豚由来:日本ハム株式会社製P-エラスチン)、クエン酸、安息香酸ナトリウムを添加し、十分に撹拌した。その後に、クエン酸鉄アンモニウムを添加し、全量の80%程度となるように精製水を加え、十分に撹拌した。次に植物エキスとして、レモンバームエキス(熱水抽出エキス、丸善製薬株式会社製レモンバームエキスパウダーMF)、ドクダミエキス(水抽出エキス、日本粉末薬品株式会社製ドクダミエキスパウダー)、アーティチョークエキス(エタノール抽出エキス、一丸ファルコス株式会社製バイオベネフィティF)、又はローズマリーエキス(熱水抽出物エキス、丸善製薬株式会社製ローズマリーエキスMF)を添加し、十分に撹拌後、塩酸または水酸化ナトリウムを用いてpHを調整し、精製水を加えて全量とし、経口液体組成物を得た(実施例1-1~18)。これらの経口液体組成物をスクリュー管No.7((株)マルエム製)に50ml充填し、80℃25分の殺菌を行った。なお、植物エキスを添加しない経口液体組成物を対照とした(比較例1~18)。
上記の通り調製した経口液体組成物を65℃で7日間保存し、においを嗅ぎ、表11の基準で不快臭の軽減度合いを評価した。
なお、表1~表10の各エキス量は、原料エキスに含まれる賦形剤と抽出溶媒を除いた正味のエキス量である。
(Comparative Examples 1 to 18, Examples 1-1 to 18)
Oral liquid compositions were prepared according to the formulations shown in Tables 1-10 below and the following methods. First, collagen peptide (derived from pig: Collagen JB manufactured by Nitta Gelatin Co., Ltd., Nippi Peptide PRA-P manufactured by Nippi Co., Ltd., derived from fish: Nippi Peptide FCP-EX manufactured by Nippi Co., Ltd.) is added to about 60% of the total amount of purified water. ), Or elastin peptide (fish-derived: bonito elastin manufactured by Hayashikane Sangyo Co., Ltd., pig-derived: P-elastin manufactured by Nippon Ham Co., Ltd.), citric acid, and sodium benzoate were added and sufficiently stirred. After that, ammonium iron citrate was added, purified water was added so as to be about 80% of the total amount, and the mixture was sufficiently stirred. Next, as plant extracts, lemon balm extract (hot water extract, lemon balm extract powder MF manufactured by Maruzen Pharmaceutical Co., Ltd.), dokudami extract (water extract, dokudami extract powder manufactured by Nippon Powder Pharmaceutical Co., Ltd.), artichoke extract (ethanol extract extract, Add Biobenefity F manufactured by Ichimaru Falcos Co., Ltd. or Rosemary extract (hot water extract, Rosemary extract MF manufactured by Maruzen Pharmaceutical Co., Ltd.), stir well, and then use hydrochloric acid or sodium hydroxide to pH. Was adjusted, and purified water was added to make the total amount to obtain an oral liquid composition (Examples 1-1 to 18). These oral liquid compositions were subjected to screw tube No. 7 (manufactured by Maruemu Co., Ltd.) was filled with 50 ml and sterilized at 80 ° C. for 25 minutes. An oral liquid composition to which no plant extract was added was used as a control (Comparative Examples 1 to 18).
The oral liquid composition prepared as described above was stored at 65 ° C. for 7 days, smelled, and the degree of reduction of unpleasant odor was evaluated according to the criteria shown in Table 11.
The amount of each extract in Tables 1 to 10 is the net amount of the extract excluding the excipient and the extraction solvent contained in the raw material extract.
表1~6に示した通り、鉄化合物およびコラーゲンペプチドを配合することにより、不快臭が生じた(比較例1~10)。コラーゲンペプチドの濃度が高まると不快臭の割合も増加した(比較例1~3)。また、鉄の濃度が高まると不快臭の割合も増加した(比較例2、4、5、7)。一方、レモンバームエキス、ドクダミエキス、アーティチョークエキス、又はローズマリーエキスを配合することにより、不快臭の割合が軽減された(実施例1-1~実施例10-3)。
表7~10に示した通り、鉄化合物およびエラスチンペプチドを配合した場合においても、不快臭が生じた(比較例11~18)。エラスチンペプチドの濃度が高まると不快臭の割合も増加した(比較例12、14,15)。また、鉄の濃度が高まると不快臭の割合も増加した(比較例12、13)。一方、レモンバームエキス、ドクダミエキス、アーティチョークエキス、又はローズマリーエキスを配合することにより、不快臭の割合が軽減された(実施例11-1~実施例18)。
As shown in Tables 1 to 6, an unpleasant odor was generated by blending the iron compound and the collagen peptide (Comparative Examples 1 to 10). As the concentration of collagen peptide increased, the proportion of unpleasant odor also increased (Comparative Examples 1 to 3). In addition, as the iron concentration increased, the proportion of unpleasant odors also increased (Comparative Examples 2, 4, 5, 7). On the other hand, by blending lemon balm extract, Houttuynia cordata extract, artichoke extract, or rosemary extract, the proportion of unpleasant odor was reduced (Examples 1-1 to 10-3).
As shown in Tables 7 to 10, an unpleasant odor was generated even when the iron compound and the elastin peptide were blended (Comparative Examples 11 to 18). As the concentration of elastin peptide increased, so did the proportion of unpleasant odors (Comparative Examples 12, 14, 15). In addition, as the concentration of iron increased, the proportion of unpleasant odors also increased (Comparative Examples 12 and 13). On the other hand, by blending lemon balm extract, Houttuynia cordata extract, artichoke extract, or rosemary extract, the proportion of unpleasant odor was reduced (Examples 11-1 to 18).
本発明により、経口液体組成物中における鉄化合物およびコラーゲンペプチド又はエラスチンペプチドを配合した際の不快臭を抑制することが可能となったので、医薬品、医薬部外品及び食品の分野において、商品性の高い鉄化合物及びコラーゲンペプチド又はエラスチンペプチド含有経口液体組成物を提供することが期待される。 INDUSTRIAL APPLICABILITY According to the present invention, it has become possible to suppress an unpleasant odor when an iron compound and a collagen peptide or an elastin peptide are blended in an oral liquid composition. It is expected to provide an oral liquid composition containing a high iron compound and a collagen peptide or an elastin peptide.
Claims (8)
(B)コラーゲンペプチド
(C)ドクダミエキス、アーティチョークエキス、及びローズマリーエキスからなる群から選ばれる少なくとも1種の植物エキス、を含有することを特徴とする経口液体組成物。 (A) Iron compound,
(B) Collagen peptide (C) An oral liquid composition comprising at least one plant extract selected from the group consisting of Houttuynia cordata extract, artichoke extract, and rosemary extract.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020192119 | 2020-11-19 | ||
JP2020192119 | 2020-11-19 | ||
JP2021143900A JP7082237B1 (en) | 2020-11-19 | 2021-09-03 | Beverages containing collagen and iron |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021143900A Division JP7082237B1 (en) | 2020-11-19 | 2021-09-03 | Beverages containing collagen and iron |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022081466A true JP2022081466A (en) | 2022-05-31 |
Family
ID=81799556
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021143900A Active JP7082237B1 (en) | 2020-11-19 | 2021-09-03 | Beverages containing collagen and iron |
JP2021154045A Active JP7107422B2 (en) | 2020-11-19 | 2021-09-22 | Beverages containing elastin and iron |
JP2021195865A Pending JP2022081466A (en) | 2020-11-19 | 2021-12-02 | Beverages containing collagen and iron |
JP2021195866A Pending JP2022081467A (en) | 2020-11-19 | 2021-12-02 | Beverage containing elastin and iron |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021143900A Active JP7082237B1 (en) | 2020-11-19 | 2021-09-03 | Beverages containing collagen and iron |
JP2021154045A Active JP7107422B2 (en) | 2020-11-19 | 2021-09-22 | Beverages containing elastin and iron |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021195866A Pending JP2022081467A (en) | 2020-11-19 | 2021-12-02 | Beverage containing elastin and iron |
Country Status (1)
Country | Link |
---|---|
JP (4) | JP7082237B1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6923065B1 (en) * | 2020-11-25 | 2021-08-18 | 大正製薬株式会社 | Oral solid composition |
KR102633367B1 (en) * | 2022-11-08 | 2024-02-06 | 종근당건강 주식회사 | Granule composition with agent for removing unpleasant taste and smell of collagen and method for producing the same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4715078B2 (en) | 2003-04-16 | 2011-07-06 | 大正製薬株式会社 | Liquid composition for internal use containing iron compounds |
JP6841371B1 (en) | 2020-09-02 | 2021-03-10 | 大正製薬株式会社 | Iron compound and collagen-containing composition |
JP6923065B1 (en) | 2020-11-25 | 2021-08-18 | 大正製薬株式会社 | Oral solid composition |
-
2021
- 2021-09-03 JP JP2021143900A patent/JP7082237B1/en active Active
- 2021-09-22 JP JP2021154045A patent/JP7107422B2/en active Active
- 2021-12-02 JP JP2021195865A patent/JP2022081466A/en active Pending
- 2021-12-02 JP JP2021195866A patent/JP2022081467A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2022081467A (en) | 2022-05-31 |
JP2022081403A (en) | 2022-05-31 |
JP7082237B1 (en) | 2022-06-07 |
JP2022100213A (en) | 2022-07-05 |
JP7107422B2 (en) | 2022-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5276813B2 (en) | Elastin-degrading peptide, method for producing elastin and its enzyme-degrading peptide | |
JP7082237B1 (en) | Beverages containing collagen and iron | |
KR20100014572A (en) | Process for producing osteocalcin-containing extract | |
JP5696720B2 (en) | Beverage | |
JP2012171901A (en) | Food for oral-intake for hair growth of men | |
JP2004238365A (en) | Skin beautifying agent, and beauty and health food | |
JP2007070316A (en) | Peroral composition and dietary supplement | |
JP2007320891A (en) | Oral composition for promoting skin beauty | |
JP2009142272A (en) | Beverage | |
JP7338772B2 (en) | oral solid composition | |
JP2021090412A (en) | Unpleasant taste masking agent, acidic protein beverage, unpleasant taste masking method, and method for producing acidic protein beverage | |
JP2001169752A (en) | Food composition | |
JP6841371B1 (en) | Iron compound and collagen-containing composition | |
JP4914594B2 (en) | Food composition for improving joint pain | |
JP5281895B2 (en) | Calcium absorption promoter | |
CN103478718B (en) | Improve functional food of glutathione concentration in human body and preparation method thereof | |
JP2006069967A (en) | Gray hair-suppressing composition and cosmetics including the same and eating and drinking type cosmetics | |
JP2008044890A (en) | Composition for breast enlargement and food and beverage for breast enlargement | |
JP2019041696A (en) | Oral composition | |
JP6629469B1 (en) | An antihypertensive agent comprising a chondroitin sulfate-containing porcine cartilage extract as an active ingredient and a food composition containing the same | |
JP5359527B2 (en) | Beverage | |
JP2019041687A (en) | Composition for eating and drinking | |
JP2022081425A (en) | Iron compound-containing composition | |
JP2022151696A (en) | Beverage containing iron compound and collagen | |
JPH1189512A (en) | Health hood |